Altered Protein Kinase C Regulation of Pulmonary Endothelial Store- and Receptor-Operated Ca²⁺ Entry after Chronic Hypoxia^S

Michael L. Paffett, Melissa A. Riddle, Nancy L. Kanagy, Thomas C. Resta, and Benjimen R. Walker

Vascular Physiology Group, Department of Cell Biology and Physiology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico

Received January 5, 2010; accepted June 23, 2010

ABSTRACT

Chronic hypoxia (CH)-induced pulmonary hypertension is associated with decreased basal pulmonary artery endothelial cell (EC) Ca^{2+} , which correlates with reduced storeoperated Ca^{2+} (SOC) entry. Protein kinase C (PKC) attenuates SOC entry in ECs. Therefore, we hypothesized that PKC has a greater inhibitory effect on EC SOC and receptoroperated Ca^{2+} entry after CH. To test this hypothesis, we assessed SOC in the presence or absence of the nonselective PKC inhibitor GF109203X [2-[1-(3-dimethylaminopropyl)-1*H*-indol-3-yl]-3-(1*H*-indol-3-yl)maleimide] in freshly isolated, Fura-2-loaded ECs obtained from intrapulmonary arteries of control and CH rats (4 weeks at 0.5 atm). We found that SOC entry and 1-oleoyl-2-acetyl-*sn*-glycerol (OAG)- and ATP-induced Ca^{2+} influx were attenuated in ECs from CH rats versus controls, and GF109203X restored SOC and OAG responses to the level of controls. In contrast, nonselective PKC inhibition with GF109203X or the selective PKC_e inhibitor myristoylated V1-2 attenuated ATP-induced Ca²⁺ entry in ECs from control but not CH pulmonary arteries. ATP-induced Ca²⁺ entry was also attenuated by the T-type voltage-gated Ca²⁺ channel (VGCC) inhibitor mibe-fradil in control cells. Consistent with the presence of endothelial T-type VGCC, we observed depolarization-induced Ca²⁺ influx in control cells that was inhibited by mibefradil. This response was largely absent in ECs from CH arteries. We conclude that CH enhances PKC-dependent inhibition of SOC- and OAG-induced Ca²⁺ entry. Furthermore, these data suggest that CH may reduce the ATP-dependent Ca²⁺ entry that is mediated, in part, by PKC_E and mibefradil-sensitive Ca²⁺ channels in control cells.

Introduction

Conditions associated with chronic hypoxia (CH), such as chronic bronchitis and emphysema, often lead to pulmonary hypertension. The endothelium is an important regulator of pulmonary vascular tone that may be affected by CH. It has been recently observed that basal endothelial cell (EC) $[\mathrm{Ca}^{2+}]_{\mathrm{i}}$ and store-operated Ca^{2+} (SOC) entry are reduced in pressurized intrapulmonary arteries from CH rats (Paffett et al., 2007). Because many vasodilatory pathways, such as the production of nitric oxide and prostacyclin, are Ca^{2+} -dependent, diminution of $[\mathrm{Ca}^{2+}]_{\mathrm{i}}$ could promote the vasoconstriction observed in this setting. However, the mechanism of reduced EC Ca^{2+} entry after CH has not been investigated. The present study examines the role of PKC in reduced Ca^{2+} entry.

Many families of ion channels in a variety of cell types are regulated by PKC. Some of the first reports of PKC modulating voltage-gated Ca^{2+} channels (VGCCs) were in neuronal (Ewald et al., 1988; Yang and Tsien, 1993) and vascular smooth muscle (VSM) preparations (Schuhmann and Gros-

ABBREVIATIONS: CH, chronic hypoxia; PKC, protein kinase C; $[Ca^{2+}]_i$, intracellular calcium concentration; EC, endothelial cell; SOC, store-operated Ca²⁺; CPA, cyclopiazonic acid; OAG, 1-oleoyl-2-acetyl-*sn*-glycerol; ROC, receptor-operated Ca²⁺; VGCC, voltage-gated Ca²⁺ channel; VSM, vascular smooth muscle; TRP, transient receptor potential; DAG, diacylglycerol; HBSS, HEPES-buffered saline solution; PECAM-1, platelet/endothelial cell adhesion molecule-1; IP₃, inositol trisphosphate; V1-2myr, myristoylated V1-2; GF109203X, 2-[1-(3-dimethylaminopropyl)-1*H*-indol-3-yl]-3-(1*H*-indol-3-yl]maleimide; Gö6976, 5,6,7,13-tetrahydro-13-methyl-5-oxo-12*H*-indolo[2,3-a]py rrolo[3,4-c]carbazole-12-propanenitrile; SKF96365, 1-[2-(4-methoxyphenyl))propoxy]ethyl]-1*H*-imidazole hydrochloride; U73122, 1-[6-[[(17b)-3-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1*H*-pyrrole-2,5-dione; U73343, 1-[6-[[(17 β)-3-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-pyrrolidine-2,5-dione.

This work is supported by the American Heart Association [Grant 0615551Z]; and the National Institutes of Health National Heart, Lung, and Blood Institute [Grants HL58124, HL63207, HL77876, HL88192].

Article, publication date, and citation information can be found at http://jpet.aspetjournals.org. doi:10.1124/jpet.110.165563.

[[]S] The online version of this article (available at http://jpet.aspetjournals.org) contains supplemental material.

chner, 1994). These early investigations revealed that stimulating PKC with phorbol esters can either potentiate or inhibit VGCC activity depending on the cell type or concentration of PKC agonist. Later investigations reported that thrombin-induced activation of T-type VGCCs has been characterized in the pulmonary microvasculature (Wu et al., 2003) and shown to involve PKC_{ϵ} (Park et al., 2006). In addition to modulating VGCC, PKC can target transient receptor potential (TRP) channels in the vasculature. For example, Earley et al. (2007) observed PKC-dependent activation of the mechanosensitive TRPM4 isoform that contributes to control of cerebral vascular tone. PKC also regulates members of the canonical subfamily of TRP channels known to be expressed in vascular endothelium and smooth muscle. TRPC1/4/5 isoforms are activated by depletion of intracellular Ca²⁺ stores, resulting in extracellular Ca²⁺ influx or SOC entry, whereas TRPC3/6/7 are believed to be activated in a store-independent manner by a variety of second-messenger systems and are often referred to as receptor-operated Ca²⁺ (ROC) entry [for review see Pedersen and Nilius (2007))]. PKC has been identified as both an activator of SOC entry in portal vein (Albert and Large, 2002) and an inhibitor in pulmonary artery VSM cells (Horibe et al., 2001), but there is little information regarding the role of PKC in modulating SOC and ROC entry in the vascular endothelium.

PKC isoforms are classified into three categories determined by their NH₂-terminal regulatory domain structure. Conventional PKCs (α , β_{I} , β_{II} , and γ) contain a C1 domain that binds diacylglycerol (DAG) and a C2 domain that binds anionic phospholipids in a Ca²⁺-dependent manner. Novel PKCs $(\delta, \theta, \varepsilon, \text{ and } \eta)$ are activated by DAG but not by changes in cytosolic Ca²⁺. Unlike conventional and novel PKCs, atypical PKCs (ζ and $\sqrt{\lambda}$) are characterized as DAG- and Ca²⁺insensitive, but they are activated by phosphatidylinositol trisphosphate or ceramide [for review see Gallegos and Newton (2008)]. Whereas most PKC subfamilies and their isoforms are ubiquitously expressed throughout various tissues, their regulatory actions on SOC and ROC entry vary widely. For example, PKC_{α} contributes to activation of SOC entry in cultured mesangial (Ma et al., 2002) and ECs (Ahmmed et al., 2004). Likewise, δ and β PKC isoforms are required for SOC entry in corneal epithelium (Zhang et al., 2006). Yang et al. (2008) found that nonspecific inhibition of PKC enhanced SOC entry in pulmonary artery VSM, suggesting an inhibitory rather than a potentiating role within the pulmonary vasculature. These reports highlight the diverse effects of PKC on SOC entry in the nonpathological setting; however, little is known about the role of PKC regulation of EC SOC and ROC entry after CH.

Therefore, we hypothesized that reduced EC SOC and ROC entry after CH are mediated by altered PKC-dependent regulation. We tested this hypothesis by examining the effect of different PKC inhibitors on SOC and ROC entry in freshly isolated endothelium from intrapulmonary arteries from control rats and pulmonary hypertensive animals exposed to 4 weeks of CH.

Materials and Methods

All protocols used in this study were reviewed and approved by the Institutional Animal Care and Use Committee of the University of New Mexico Health Sciences Center. **Exposure of Rats to Chronic Hypoxia.** Male Sprague-Dawley rats (200–250 g; Harlan, Indianapolis, IN) were used for all studies. CH exposure consisted of housing rats in a pressure-controlled environment (\sim 380 torr) for 4 weeks. Age-matched control rats were boarded in similar cages under ambient barometric pressure (\sim 630 torr). The hypobaric chamber was opened three times a week to provide fresh rat chow, water, and clean bedding.

Isolation and Preparation of Pulmonary Artery Endothelial Cells. Rats were euthanized with sodium pentobarbital (200 mg/kg i.p.), and the left lung was rapidly excised and placed in HEPES-buffered saline solution (HBSS). The HBSS contained 150 mM NaCl, 6 mM KCl, 1 mM MgCl₂, 1.8 mM CaCl₂, 10 mM HEPES, and 10 mM glucose, titrated to pH 7.4 with NaOH. Intrapulmonary arteries (third and fourth order; 200–400 μ m i.d.) were dissected from the cranial most region of the left lung and carefully cleaned of surrounding lung parenchyma. Endothelial sheets were enzymatically dissociated and stored for up to 5 h at 4°C as described previously (Paffett et al., 2007). Freshly isolated rat pulmonary artery endothelial cells were then placed on a poly-L-lysine-coated glassbottom 35-mm culture dish (BD Biosciences, San Jose, CA) with a small bore fire-polished Pasteur pipette and allowed to equilibrate for 30 min at room temperature before experimentation.

Fura-2 Loading of Freshly Isolated Endothelial Sheets. Ca^{2+} entry was determined in freshly isolated endothelial sheets by using the ratiometric Ca^{2+} -sensitive dye Fura-2 AM (Invitrogen). Endothelial sheets were loaded with 3 μ M Fura-2 AM (0.05% pluronic acid) in HBSS for 5 min at ~23°C and washed for 15 min at 37°C. Ratiometric changes in endothelial cell $[Ca^{2+}]_i$ were acquired by alternating specimen excitation for 50 ms between 340- and 380-nm bandpass filters at 1 Hz (Hyperswitch; Ionoptix, Milton, MA) in which the interleaved Fura-2 emissions at 510 nm were detected with a photomultiplier tube.

Assessing the Role of PKC-Dependent Modulation of SOC and ROC Entry. After a 30-min recovery period and Fura-2 loading, endothelial sheets were superfused with HBSS at 37°C and then switched to Ca^{2+} -free HBSS (equimolar Mg^{2+} substitution) for 2 to 3 min. Passive depletion of intracellular Ca^{2+} stores by inhibition of the sarco/endoplasmic reticulum Ca^{2+} ATPase with 10 μ M cyclopiazonic acid (CPA) was performed, and SOC entry was defined as the change in 340/380 fluorescence after repletion of extracellular Ca^{2+} (Fig. 1). After the SOC entry response, stabilized ROC entry was assessed by the addition of OAG (100 μ M) or ATP (20 μ M) in the continued presence of CPA. Any further increase in Fura-2 ratio was



Fig. 1. Experimental protocol depicting assessment of endothelial SOC and ROC entry. SOC entry was defined by a change in F_{340}/F_{380} (ΔR) in freshly isolated endothelial cells depleted of intracellular Ca²⁺ stores with 10 μ M CPA before the readdition of extracellular Ca²⁺. Endothelial ROC entry was defined similarly and assessed by application of OAG (100 μ M) or ATP (20 μ M) after the stabilization of the SOC response. Depolarization-induced entry was assessed in a likewise fashion with high extracellular K⁺. PKC, PLC, and Ca²⁺ channel inhibitors were administered in separate protocols.

defined as ROC entry (Fig. 1) as described previously (Jernigan et al., 2006). In separate experiments, ROC entry was assessed in cells preincubated for 10 min with the nonspecific inhibitor of PKC [GF109203X (2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl)maleimide)] (1 μ M) before the reapplication of extracellular Ca²⁺ and ROC entry agonist. In parallel experiments, the cell-permeant PKC_ε peptide inhibitor (V1-2myr) (10 μ M) or a concentration-specific PKC_{α/β} inhibitor (Gö6976) [5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]py rrolo[3,4-c]carbazole-12-propanenitrile] (6 nM) was applied for period of 10 min before the addition of ATP.

Effect of Ca²⁺ Channel Blockers on ATP-Induced Ca²⁺ Entry. To determine whether ATP-induced ROC entry is mediated by voltage-dependent Ca^{2+} channels, we examined Ca^{2+} responses to ATP in store-depleted endothelial cells from control and CH arteries preincubated with the putative T-type Ca²⁺ channel inhibitor mibefradil (10 μM), the L-type Ca²⁺ channel inhibitor diltiazem (50 μM), the nonselective Ca²⁺ channel blocker SKF96365 [1-[2-(4-methoxyphenyl)-2-[3-(4-methoxyphenyl)propoxy]ethyl]-1H-imidazole hydrochloride] (20 µM), or vehicle for 5 min before stimulation with ATP. These concentrations of diltiazem and mibefradil have been reported previously to selectively inhibit L-and T-type VGCCs, respectively (Wei et al., 2004; Zhou et al., 2007). Furthermore, we performed validation experiments using patch-clamp techniques to confirm the selective inhibitory actions of mibefradil and diltiazem in neonatal cardiomyocytes and pulmonary artery vascular smooth muscle cells. respectively (see Supplemental Figs. 1 and 2).

Role of PLC, Mibefradil-Sensitive Ca²⁺ Channels, and PKC_e in ATP-Induced Ca²⁺ Entry. Additional experiments were conducted to confirm that ATP-induced Ca²⁺ entry involves PLCinitiated signaling events. After the development of a stable SOC entry response, 20 μ M ATP was added in the presence of the PLC inhibitor U73122 [1-[6-[[(17b)-3-methoxyestra-1,3,5(10)-trien-17yl]amino]hexyl]-1H-pyrrole-2,5-dione] (3 μ M) or its inactive analog U73343 [1-[6-[[(17\beta)-3-methoxyestra-1,3,5(10)-trien-17yl]amino]hexyl]-pyrrolidine-2,5-dione] (3 μ M). To corroborate the involvement of T-type Ca²⁺ channels in ATP-induced entry, parallel experiments were performed in the presence of mibefradil. Furthermore, to determine whether PKC_e and T-type Ca²⁺ channel activation were operating in parallel after the addition of ATP, we assessed ATP-induced Ca²⁺ influx in the presence of mibefradil and the myristoylated V1-2 peptide PKC_e inhibitor.

Endothelial Ca²⁺ Responses to Extracellular KCl. Because results of the above studies suggested the presence of endothelial VGCCs, the response to depolarizing concentrations of KCl (15, 30, 60, and 90 mM) was assessed in cells from control and CH rats. Parallel experiments were performed in which the KCl-selective ionophore valinomycin (5 μ M) was present to rule out the possibility of unequal K⁺ conductance differentially regulating E_m between groups. To determine the potential involvement of L- and T-type voltage-sensitive Ca²⁺ channels, a 60-mM KCl depolarizing stimulus was applied in the presence or absence of the inhibitors diltiazem and mibefradil. Furthermore, to rule out any potential tonic influences of store-operated Ca²⁺ entry on the depolarizing effects of KCl, these experiments were conducted in the presence of CPA to inhibit sarco/endoplasmic reticulum Ca²⁺ ATPase.

Qualitative Immunofluorescence of Ca_v3.1 (α 1G) in the Pulmonary Endothelium. Freshly isolated pulmonary arterial endothelium from control or CH animals were fixed in 4% paraformaldehyde at room temperature for 10 min. After fixation, all samples were permeabilized with 0.01% Triton X-100 and phosphate-buffered saline for 10 min and blocked with 3% donkey serum in phosphatebuffered saline for 1 h at room temperature. Fixed cells were incubated with primary antibodies for the Ca_v3.1 (α 1G) T-type VGCC subunit (1:100; rabbit polyclonal) and PECAM-1 (1:200; mouse monoclonal) (Transduction Laboratories, Lexington, KY) overnight at 4°C. Primary antibodies were detected with Cy5-conjugated donkey anti-rabbit and Cy3-conjugated donkey anti-mouse secondary antibodies (1:500 dilution; Jackson ImmunoResearch Laboratories Inc., West Grove, PA). Nuclei were stained with Sytox (1:10,000 dilution; Invitrogen, Carlsbad, CA) and applied to all samples. Specimens were visualized with a confocal laser microscope (LSM 510; Carl Zeiss Inc., Thornwood, NY) with a $63 \times$ oil immersion lens.

Calculations and Statistics. All data are expressed as means \pm S.E. Values of *n* refer to the number of endothelial sheets (40–100 cells/sheet) in which one to two sheets were studied from one rat. A one-way or two-way analysis of variance was used where appropriate for all comparisons between control and CH groups. If differences were detected by analysis of variance, individual groups were compared with the Student-Newman-Keuls test. Probability of ≤ 0.05 was accepted as statistically significant for all comparisons.

Results

Differential PKC Regulation of SOC and ROC Entry. Both SOC and ROC entry were diminished in cells from CH compared with control arteries (Fig. 2). Diminished ROC entry was seen in experiments using OAG (Fig. 2) and those using ATP (Fig. 3) as an agonist. Nonselective PKC inhibition with GF109203X restored both SOC and OAG-induced Ca^{2+} entry in endothelial cells isolated from CH arteries to the level of controls without affecting the control group (Fig. 2). In contrast, GF109203X reduced ATP-induced Ca^{2+} responses in endothelial cells from control arteries (Fig. 3).



Fig. 2. PKC inhibition restores endothelial SOC and OAG-induced ROC entry in endothelial cells from CH rats. A, endothelial SOC entry was measured as a change in F_{340}/F_{380} (ΔR) fluorescence upon repletion of extracellular Ca²⁺ (1.8 mM) in the presence or absence of the nonselective PKC inhibitor GF109203X. B, serial assessment of endothelial ROC entry was performed by evaluating OAG-induced Ca²⁺ entry (ΔR) after the SOC response in the presence or absence of GF109203X. Values are mean \pm S.E. *n* is the number of endothelial sheets (40–100 cells/sheet) and is indicated within the data bars. $P \leq 0.05$: *, versus control vehicle; **, versus CH vehicle.



Fig. 3. PKC inhibition blunts ATP-induced Ca²⁺ influx in endothelium from controls but not from CH pulmonary arteries. ATP-induced Ca²⁺ entry (ΔR) was assessed after the SOC response in the presence of vehicle, the nonselective PKC inhibitor GF109203X (1 μ M), the PKC_e inhibitor V1-2myr (10 μ M), or the PKC_{α/β} inhibitor G6976 (6 nM). Values are mean \pm S.E. *n* is the number of endothelial sheets (40–100 cells/sheet) and is indicated within the data bars. $P \leq 0.05$: *, versus control vehicle; **, versus control vehicle.

Likewise, PKC_e inhibition with V1-2myr effectively blunted ATP-induced Ca²⁺ entry in control endothelium, whereas PKC_{α/β} inhibition with Gö6976 had no effect. In contrast to control cells, pan-specific inhibition of PKCs or selective PKC_{α/β} or PKC_e inhibition did not affect the blunted ATP-induced Ca²⁺ response in the CH group. These results demonstrate that CH exposure results in a generalized reduction in Ca²⁺ entry; however, there seems to be differential regulation by various PKC isoforms depending on the mode of activation.

Effect of Ca^{2+} Channel Blockers on ATP-Induced Ca^{2+} Entry. Inhibition of T-type Ca^{2+} channels with mibefradil blunted ATP-induced Ca^{2+} entry in endothelial cells from control rats compared with vehicle but was without effect in cells from CH rats (Fig. 4). Likewise, the nonselective inhibitor of voltage-dependent Ca^{2+} channels SKF96365 reduced entry only in control cells. In contrast, L-type Ca^{2+} channel inhibition was ineffective at blocking ROC entry in either group.

Role of PLC, Mibefradil-Sensitive Ca²⁺ Channels, and PKC_{ε} in ATP-Induced Ca²⁺ Entry. Experiments were performed with U73122 to verify that ATP-induced



Fig. 4. Receptor-mediated (ATP) Ca²⁺ influx involves T-type VGCCs in endothelium from controls but not CH pulmonary arteries. Experiments were conducted after the SOC response in the presence of VGCC inhibitors: 10 μ M mibefradil, 50 μ M diltiazem, or 20 μ M SKF96365. Values are mean \pm S.E. (n = 5/group). $P \leq 0.05$: *, versus control; **, versus control vehicle.



Fig. 5. Receptor-mediated (ATP) Ca²⁺ influx operates through a PLCdependent mechanism that potentially requires PKC_e to activate T-type VGCCs in endothelium from controls but not CH pulmonary arteries. PLC-dependent signaling through PKC_e, and T-type VGCCs in ATPinduced Ca²⁺ entry was examined in endothelium from control and CH pulmonary arteries. Experiments were conducted after the SOC entry response in the presence of U73122 (3 μ M), U73343 (3 μ M), mibefradil (10 μ M), and V1-2myr (10 μ M). Values are expressed as means \pm S.E. (n = 5/group). $P \leq 0.05$: *, versus inactive analog control; **, versus inactive analog CH; #, versus U73343 control.

responses involved PLC-initiated events. PLC inhibition with U73122 abolished ATP-induced Ca^{2+} responses in endothelial cells from both control and CH arteries, whereas the inactive analog U73343 of this inhibitor had no effect (Fig. 5). Furthermore, as seen in previous protocols, mibe-fradil reduced ROC entry in only the control group. When mibefradil was combined with the PKC_e inhibitor, V1-2myr, no additive effect was observed. It is noteworthy that neither of these inhibitors had an effect on ATP-induced Ca^{2+} entry in endothelial cells from CH arteries.

Endothelial Ca²⁺ Responses to Extracellular KCl. Application of increasing concentrations of extracellular KCl increased endothelial cell Ca^{2+} in control cells (Fig. 6A); however, this response was greatly attenuated in ECs from CH arteries (Fig. 6B). These differences persisted when endothelial K^+ permeability and hence E_m was equivalently clamped with valinomycin across all KCl concentrations (Fig. 6C), demonstrating that unequal K^+ permeability does not account for the observed differences between groups. Additional experiments showed that the Ca²⁺ response to 60 mM KCl was inhibited by the T-type antagonist mibefradil in control cells, but had no effect in cells from CH rats. The L-type channel inhibitor diltiazem did not affect either group. These data suggest that mibefradil-sensitive T-type VGCCs account for depolarization-induced Ca²⁺ entry in control cells and that this response is lost after CH.

Qualitative Immunofluorescence of Ca_v3.1 (α 1G) in the Pulmonary Endothelium. Ca_v3.1 immunofluorescence was detected in the endothelium from control rats and seemed to be peripherally located (Fig. 7, top). Immunofluorescence was also detected in endothelium from CH vessels; however, Ca_v3.1 fluorescence seemed to be less abundant at the cell periphery (Fig. 7, middle). Primary antibody specificity was confirmed with the blocking antigen, and endothelial cells were positively identified by a PECAM-1 label (Fig. 7, bottom).



Fig. 6. Endothelial cell Ca^{2+} increases in response to increasing K⁺ concentrations. A, representative trace illustrating endothe lial cell Ca^{2+} response to incremental K⁺ concentrations measured by Fura-2 in control cells. B, summary data illustrating K⁺-dependent Ca²⁺ responses in endothelium from control and CH pulmonary arteries. KCl-induced Ca²⁺ responses were less at all K⁺ concentrations in cells from CH rats compared with controls. C, K⁺induced Ca2+ influx was also performed in the presence of the K⁺-selective ionophore valinomycin (5 μ M). Values are expressed as means \pm S.E. (n = 4/group). $P \leq 0.05$: *, versus control; **, versus 15 mM K⁺ concentration. D, summary data illustrating reduced Ca²⁺ entry after CH in response to 60 mM K⁺ and the effects of VGCC channel inhibition in control endothelial cells. Diltiazem (50 µM) and 10 µM mibefradil were used to selectively inhibit L-type and Ttype VGCCs, respectively. ΔR is defined by change in F_{340}/F_{380} . Values are expressed as means \pm S.E. (n = 4/group). $P \le 0.05$: *, versus control; **, versus control vehicle and control diltiazem.

Discussion

The present study illustrates the differential regulation of endothelial SOC and ROC entry pathways by PKC after CH-induced pulmonary hypertension. The major findings of this study are: 1) SOC entry and OAG- and ATP-induced Ca²⁺ influx pathways are attenuated in freshly dissociated endothelium from CH pulmonary arteries compared with controls; 2) nonselective inhibition of PKC restores SOC and OAG responses in endothelium from CH rats to the level of controls; 3) PKC_{ε} inhibition attenuates ATPinduced Ca²⁺ entry in endothelium from control but not CH pulmonary arteries; 4) ATP-induced Ca²⁺ entry was inhibited by mibefradil in control but not CH endothelia; and 5) CH attenuates high K^+ -induced Ca^{2+} entry, whereas this response was present in control ECs and blocked by mibefradil. Taken together, these findings suggest that CH up-regulates PKC-dependent inhibition of SOC- and OAG-induced Ca²⁺ entry. Furthermore, these data also suggest that CH reduces PLC-dependent Ca²⁺ entry that seems to be mediated, in part, by PKC_{ε} and mibefradilsensitive Ca²⁺ channels in control cells. Impaired Ca²⁺ entry after CH could significantly diminish production and release of important vasodilatory mediators, thereby exacerbating the severity of pulmonary hypertension.

In most cells, receptor-dependent activation of PLC stimulates the production of IP₃ and subsequent release of Ca²⁺ from intracellular stores, which leads to plasmalemmal Ca²⁺ influx. The store-dependent arm of this signaling pathway is activated by IP₃ binding to IP₃ receptors, depleting endoplasmic reticulum Ca²⁺ and stimulating SOC entry. However, there is considerable evidence that PLC-dependent DAG production mediates store-independent Ca²⁺ influx (Cheng et

al., 2006; Leung et al., 2006). The present study demonstrates that endothelial cells from small pulmonary arteries possess store-independent Ca²⁺ entry elicited by either OAG or ATP application after CPA-induced store depletion (Fig. 2B). Furthermore, our results are consistent with studies that suggest DAG directly activates TRPC channels in endothelial cells (Pocock et al., 2004). In addition to exogenous DAG analogs, endogenous DAG has been shown to stimulate Ca²⁺ influx independent of PKC activation (Gamberucci et al., 2002; Trebak et al., 2003). The current understanding from those reports and others is that DAG stimulates TRPC3/6/7 isoforms, leading to Ca²⁺ influx, but that TRPC1/4/5 isoforms are not involved in DAGdependent Ca²⁺ influx [reviewed in (Pedersen and Nilius, 2007)]. It is noteworthy that our results show reduced OAG- and ATP-dependent Ca²⁺ entry is reduced in CHinduced pulmonary hypertension.

The role of DAG-activated PKC in regulating SOC/ROC entry is controversial. Broad-spectrum PKC activators inhibit SOC entry in human neutrophils (Montero et al., 1993) and SOC entry-mediated photoreceptor activation (Hardie et al., 1993) in *Drosophila*. Furthermore, Venkatachalam et al. (2003) demonstrated that $PLC_{\gamma 2}$ -dependent activation of TRPC3/4/5 Ca²⁺ influx is negatively regulated by PKC secondary to cytosolic Ca²⁺ and/or DAG accumulation after receptor activation. Likewise, our findings suggest that PKC inhibits SOC- and OAG-induced Ca²⁺ entry after CH (Fig. 2); however, this mechanism was not evident in endothelial cells from control rats.

To further characterize the effects of CH on ROC entry and how PKC may be regulating Ca^{2+} influx, we examined purinergic receptor-stimulated Ca^{2+} influx. Consistent with ef-



Fig. 7. Immunofluorescence of $Ca_v3.1$ ($\alpha 1G$) T-type VGCC subunit (green) in freshly isolated endothelial cells from small pulmonary arteries harvested from control (top) and CH (middle and bottom) rats (magnification: ×630). Top and middle, images for control (top) and CH (middle) show detectable $Ca_v3.1$ channel subunit fluorescence (indicated by yellow arrows). Bottom left, coincubation with the blocking peptide prevented $Ca_v3.1$ immunofluorescence. Bottom right, positive PECAM-1 immunofluorescence is shown in blue. $Ca_v3.1$ and Sytox nuclear stain is in white in all cases.

fects on SOC entry and OAG-induced Ca²⁺ influx, we found ATP-induced Ca²⁺ influx was decreased in CH compared with control endothelia. Although we observed a similar decrease in Ca²⁺ influx to SOC- and OAG-induced Ca²⁺ entry after CH, it seems that purinergic receptor activation may lead to a distinct signaling cascade requiring PKC activation to stimulate ROC entry in only control endothelial cells (Fig. 3). Similar findings by Lee et al. (1997) found that 30 µM ATP promoted PKC-dependent activation of ROC entry, whereas 300 µM ATP evoked PKC-dependent inhibition of this response. That earlier report suggests PKC activates Ca²⁺ influx at concentrations of ATP similar to those used in the current study. The apparently opposing roles for PKC in regulating endothelial cell ROC entry depending on the mode of activation (i.e., OAG versus ATP) suggests that different signaling cascades are activated by these approaches. Pharmacological characterization of ATP-induced Ca²⁺ entry revealed that PKC_e seems to be a key regulator in control cells but that this mode of activation may be lost after CH. Although this possibility is likely, the use of submaximal concentrations of Ca2+ channel and/or PKC inhibitors could influence our conclusion that CH impairs Ca²⁺ influx. However, the concentrations of mibefradil and diltiazem used were effective at abolishing Ca²⁺ currents in cells known to express the targeted channels (see Supplemental Figs. 1 and 2). Thus, the residual Ca²⁺ influx mediated by KCl and ATP may represent diltiazem- and mibefradil-insensitive Ca²⁺ entry pathways that are still intact in endothelial cells from either experimental group. This interpretation of residual Ca²⁺ entry is further supported by the finding that PLC blockade abrogates ATP-induced Ca²⁺ influx in control and CH endothelial cells (Fig. 5), suggesting either PKC inhibitor concentrations were submaximal (particularly PKC_{α/β} inhibition with Gö6976) or intact Ca²⁺ entry pathways were not regulated by PKCs, accounting for this residual Ca²⁺ influx.

CH could decrease PLC activity or PKC_e activity, thereby limiting downstream activation of ROC entry. Information concerning altered PLC and PKC_e activities in the pulmonary endothelium after CH is limited. However. attenuated PLC-dependent Ca²⁺ mobilization in myometrial smooth muscle exposed to hypobaric hypoxia has been reported (Arakawa et al., 2004). In addition, acute hypoxic exposure decreases phosphoinositide synthesis in carotid bodies (Rigual et al., 1999). Later studies demonstrated increased PKC_{α} and PKC_{δ} expression but reductions in $PKC_{\beta II}$, PKC_{γ} , and PKC_{ϵ} in hypertrophied right ventricles from CH rats (Uenoyama et al., 2010), suggesting differential effects on PKC expression by CH. Although this finding supports the differential regulation of various PKC isoforms by CH, further investigation into the effects of CH on pulmonary endothelial PKC and the disparate roles they play in regulating Ca^{2+} influx is warranted.

Until recently, there has been limited support for the existence and/or role for T-type VGCCs in the pulmonary endothelium. However, molecular (De Proost, et al., 2007) and biophysical and pharmacological (Wu et al., 2003) evidence of Ca_v3.1 T-type VGCCs in the pulmonary microcirculation supports our observation that endothelial cells freshly dissociated from small pulmonary arteries express functional T-type VGCCs. This conclusion was corroborated by demonstration of Ca_v3.1 T-type VGCC expression by immunofluorescence (Fig. 7). However, our findings that KCl-induced Ca²⁺ entry is reduced (Fig. 6, B and C) and insensitive to the T-type channel inhibitor mibefradil (Fig. 6D) in endothelial cells from CH-hypertensive arteries indicate a functional and/or expressional sensitivity of this Ca²⁺ channel to CH.

A potential caveat of this interpretation is nonspecific actions of mibefradil on L-type VGCCs. However, there was no effect of diltiazem on KCl-induced Ca²⁺ influx in endothelial cells from pulmonary normotensive rats (Fig. 6), indicating a benzothiazepine (diltiazem) insensitivity to depolarizationinduced Ca²⁺ entry. Furthermore, the specific inhibitory actions of mibefradil and diltiazem were documented in neonatal cardiomyocytes and pulmonary artery vascular smooth muscle cells, respectively (see Supporting Text). Similar patch-clamp experiments were attempted in freshly dispersed endothelial sheets (data not shown), but space-clamping prevented precise control of membrane potential because these cells seem to have intact intercellular communication, leading to a very large capacitance proportional to the number of cells in a given sheet. Furthermore, we were unable to observe an inward rectifying Ca²⁺ current with the classic biophysical (rapid activation and inactivation) signature of T-type VGCCs in electrically isolated single endothelial cells (data not shown). It is possible that the elusive nature of identifying T-type VGCCs in the single-cell preparation is caused by a small subpopulation of endothelial cells that actually express T-type VGCCs. Unfortunately, these technical limitations prevented the complete dissection of the biophysical nature and pharmacology properties of the observed Ca^{2+} channels and the involved PKC isoforms.

In addition, our data suggest that depolarizing stimuli (high K^+) promote endothelial Ca^{2+} entry from control but not CH rats. This finding was somewhat surprising, because there is a lack of consensus that VGCCs exist in the pulmonary endothelium. Similar to the relatively absent KCl-induced Ca²⁺ influx after CH, we found that receptor-mediated (ATP) Ca²⁺ influx was also reduced after CH. These parallel observations of absent Ca²⁺ influx pathways led us to hypothesize that VGCCs are activated by purinoceptor stimulation. Therefore, it is possible that T-type VGCCs represent another mode of ROC entry that is sensitive to PKC activation. Consistent with this hypothesis are multiple findings (Park et al., 2003, 2006; Chemin et al., 2007; Kim et al., 2007) illustrating that PKC activation stimulates Cav3.1 and Ca_v3.2 Ca²⁺ currents. Although the specific PKC isoforms modulating Ca²⁺ influx through T-type VGCCs were not determined in those prior reports, our data suggest that PKC_s plays a role in stimulating Ca^{2+} influx in the pulmonary endothelium. Moreover, the lack of sensitivity to both V1-2myr and mibefradil and the inability of 60 mM KCl to elicit significant changes in Ca²⁺ influx in cells from CH rats compared with controls suggests that T-type VGCCs may be down-regulated at the expressional level or possibly not appropriately localized on the plasma membrane. Although this study did not examine ion channel trafficking or expression because of protein sample limitations, further experiments are needed to support these speculations.

It is also possible that ATP binds to P2X receptors, leading to membrane depolarization through nonselective cation influx and activation of T-type Ca^{2+} channels. It is generally accepted that ionotropic P2X receptors are expressed in smooth muscle and contribute to vasoconstriction (Matsuura et al., 2004); however, more recent evidence shows a novel role for P2X activation in endothelium-dependent vasodilation (Harrington et al., 2007). Although there are no known reports, it is possible that CH leads to a decrease in purinergic receptor expression in the pulmonary endothelium. We are unable to completely rule out the possibility that P2X activation leads to membrane depolarization and subsequent Ca²⁺ influx or whether purinergic receptor expression is down-regulated after CH. PLC inhibition did, however, abolish residual Ca²⁺ response to ATP in both groups, indicating that P2X receptor activation does not play a role in this response. PKC, inhibition diminished Ca²⁺ influx similar to T-type channel blockade, suggesting that PKC_s and T-type VGCCs are serially activated, assuming maximal PKC_e inhibition was achieved. Endothelial cells from CH arteries were also insensitive to either of these antagonists, and the Ca²⁺ response was strikingly similar to that in control endothelial cells when PKC_e and T-type VGCCs were inhibited, indicating that residual DAG-dependent Ca²⁺ influx pathways may not differ between groups.

Although the effects of CH on Ca^{2+} entry have been examined in pulmonary VSM (Jernigan et al., 2006), little is



Fig. 8. Diagram depicting the hypothesized effects of CH on purinergic stimulation of a mibefradil-sensitive Ca²⁺ entry pathway via PKC_e or high extracellular K⁺ in pulmonary endothelium from intrapulmonary arteries. Mibefradil (T-type channel blocker), U73122 (PLC inhibitor), and V1-2myr (PKC_e inhibitor) are shown.

known regarding effects of this stimulus on the endothelium. It is possible that CH decreases endothelial expression of TRP channels to mediate decreased SOC and ROC entry, but our findings suggest that differential PKC regulation of these pathways more likely contributes to the impaired endothelial Ca^{2+} influx observed in pulmonary hypertension. In conclusion, the present study establishes that there is a generalized decrease in endothelial Ca^{2+} entry in the pulmonary hypertensive vasculature involving PKC that could significantly impair production of endothelium-derived vasodilators. In addition, we provide evidence of a novel PKC-dependent regulation of agonist-induced Ca^{2+} entry that may involve a mibefradil-sensitive Ca^{2+} entry pathway and is impaired after CH (Fig. 8).

Acknowledgments

We thank Minerva Murphy for maintaining the hypobaric chambers used in this study.

References

- Ahmmed GU, Mehta D, Vogel S, Holinstat M, Paria BC, Tiruppathi C, and Malik AB (2004) Protein kinase C α phosphorylates the TRPC1 channel and regulates storeoperated Ca²⁺ entry in endothelial cells. *J Biol Chem* **279:**20941–20949.
- Albert AP and Large WA (2002) Activation of store-operated channels by noradrenaline via protein kinase C in rabbit portal vein myocytes. J Physiol 544:113–125.
- Arakawa TK, Mlynarczyk M, Kaushal KM, Zhang L, and Ducsay CA (2004) Longterm hypoxia alters calcium regulation in near-term ovine myometrium. *Biol Reprod* 71:156-162.
- Chemin J, Mezghrani A, Bidaud I, Dupasquier S, Marger F, Barrère C, Nargeot J, and Lory P (2007) Temperature-dependent modulation of CaV3 T-type calcium channels by protein kinases C and A in mammalian cells. *J Biol Chem* **282:**32710– 32718.
- Cheng HW, James AF, Foster RR, Hancox JC, and Bates DO (2006) VEGF activates receptor-operated cation channels in human microvascular endothelial cells. Arterioscler Thromb Vasc Biol 26:1768–1776.
- De Proost I, Brouns I, Pintelon I, Timmermans JP, and Adriaensen D (2007) Pulmonary expression of voltage-gated calcium channels: special reference to sensory airway receptors. *Histochem Cell Biol* **128**:301–316.
- Earley S, Straub SV, and Brayden JE (2007) Protein kinase C regulates vascular myogenic tone through activation of TRPM4. Am J Physiol Heart Circ Physiol 292:H2613-H2622.
- Ewald DA, Matthies HJ, Perney TM, Walker MW, and Miller RJ (1988) The effect of down-regulation of protein kinase C on the inhibitory modulation of dorsal root ganglion neuron Ca²⁺ currents by neuropeptide Y. *J Neurosci* **8**:2447–2451.
- Gallegos LL and Newton AC (2008) Spatiotemporal dynamics of lipid signaling: protein kinase C as a paradigm. *IUBMB Life* **60**:782-789.
- Gamberucci A, Giurisato E, Pizzo P, Tassi M, Giunti R, McIntosh DP, and Benedetti A (2002) Diacylglycerol activates the influx of extracellular cations in T-lymphocytes independently of intracellular calcium-store depletion and possibly involving endogenous TRP6 gene products. *Biochem J* **364**:245–254.
- Hardie RC, Peretz A, Suss-Toby E, Rom-Glas A, Bishop SA, Selinger Z, and Minke B (1993) Protein kinase C is required for light adaptation in *Drosophila* photoreceptors. *Nature* 363:634-637.
- Harrington LS, Evans RJ, Wray J, Norling L, Swales KE, Vial C, Ali F, Carrier MJ,

760 Paffett et al.

and Mitchell JA (2007) Purinergic 2X1 receptors mediate endothelial-dependent vasodilation to ATP. *Mol Pharmacol* **72:**1132–1136.

- Horibe M, Kondo I, Damron DS, and Murray PA (2001) Propofol attenuates capacitative calcium entry in pulmonary artery smooth muscle cells. *Anesthesiology* 95:681-688.
- Jernigan NL, Broughton BR, Walker BR, and Resta TC (2006) Impaired NOdependent inhibition of store- and receptor-operated calcium entry in pulmonary vascular smooth muscle after chronic hypoxia. Am J Physiol Lung Cell Mol Physiol 290:L517–L525.
- Kim Y, Park MK, Uhm DY, and Chung S (2007) Modulation of T-type Ca²⁺ channels by corticotropin-releasing factor through protein kinase C pathway in MN9D dopaminergic cells. *Biochem Biophys Res Commun* 358:796-801.
- Lee H, Suh BC, and Kim KT (1997) Feedback regulation of ATP-induced Ca²⁺ signaling in HL-60 cells is mediated by protein kinase A- and C-mediated changes in capacitative Ca²⁺ entry. J Biol Chem 272:21831–21838.
- In capacitative of the state o
- Ma R, Kudlacek PE, and Sansom SC (2002) Protein kinase $C\alpha$ participates in activation of store-operated Ca²⁺ channels in human glomerular mesangial cells. Am J Physiol Cell Physiol **283:**C1390–C1398.
- Matsuura M, Saino T, and Satoh Y (2004) Response to ATP is accompanied by a Ca²⁺ influx via P2X purinoceptors in the coronary arterioles of golden hamsters. Arch Histol Cytol 67:95-105.
- Montero M, Garcia-Sancho J, and Alvarez J (1993) Inhibition of the calcium storeoperated calcium entry pathway by chemotactic peptide and by phorbol ester develops gradually and independently along differentiation of HL60 cells. J Biol Chem 268:26911–26919.
- Paffett ML, Naik JS, Resta TC, and Walker BR (2007) Reduced store-operated Ca²⁺ entry in pulmonary endothelial cells from chronically hypoxic rats. Am J Physiol Lung Cell Mol Physiol **293:**L1135–L1142.
- Park JY, Jeong SW, Perez-Reyes E, and Lee JH (2003) Modulation of Ca(v)3.2 T-type Ca²⁺ channels by protein kinase C. FEBS Lett **547:**37–42.
- Park JY, Kang HW, Moon HJ, Huh SU, Jeong SW, Soldatov NM, and Lee JH (2006) Activation of protein kinase C augments T-type Ca²⁺ channel activity without changing channel surface density. J Physiol 577:513–523.
- Pedersen SF and Nilius B (2007) Transient receptor potential channels in mechanosensing and cell volume regulation. *Methods Enzymol* 428:183-207.
- Pocock TM, Foster RR, and Bates DO (2004) Evidence of a role for TRPC channels in VEGF-mediated increased vascular permeability in vivo. Am J Physiol Heart Circ Physiol 286:H1015-H1026.

- Rigual R, Cachero MT, Rocher A, and González C (1999) Hypoxia inhibits the synthesis of phosphoinositides in the rabbit carotid body. *Pflugers Arch* 437:839-845.
- Schuhmann K and Groschner K (1994) Protein kinase C mediates dual modulation of L-type Ca²⁺ channels in human vascular smooth muscle. *FEBS Lett* **341:**208–212.
- Trebak M, St J Bird G, McKay RR, Birnbaumer L, and Putney JW Jr (2003) Signaling mechanism for receptor-activated canonical transient receptor potential 3 (TRPC3) channels. *J Biol Chem* **278:**16244–16252.
- Uenoyama M, Ogata S, Nakanishi K, Kanazawa F, Hiroi S, Tominaga S, Seo A, Matsui T, Kawai T, and Suzuki S (2010) Protein kinase C mRNA and protein expressions in hypobaric hypoxia-induced cardiac hypertrophy in rats. Acta Physiol (Oxf) 198:431-440.
- Venkatachalam K, Zheng F, and Gill DL (2003) Regulation of canonical transient receptor potential (TRPC) channel function by diacylglycerol and protein kinase C. J Biol Chem 278:29031–29040.
- Wei Z, Manevich Y, Al-Mehdi AB, Chatterjee S, and Fisher AB (2004) Ca²⁺ flux through voltage-gated channels with flow cessation in pulmonary microvascular endothelial cells. *Microcirculation* 11:517–526.
- Wu S, Haynes J Jr, Taylor JT, Obiako BO, Stubbs JR, Li M, and Stevens T (2003) Cav3.1 (α 1G) T-type Ca²⁺ channels mediate vaso-occlusion of sickled erythrocytes in lung microcirculation. *Circ Res* **93**:346–353.
- Yang J and Tsien RW (1993) Enhancement of N- and L-type calcium channel currents by protein kinase C in frog sympathetic neurons. *Neuron* 10:127–136.
- Yang M, Ding X, and Murray PA (2008) Differential effects of intravenous anesthetics on capacitative calcium entry in human pulmonary artery smooth muscle cells. *Am J Physiol Lung Cell Mol Physiol* **294**:L1007–L1012.
- Zhang F, Wen Q, Mergler S, Yang H, Wang Z, Bildin VN, and Reinach PS (2006) PKC isoform-specific enhancement of capacitative calcium entry in human corneal epithelial cells. *Invest Ophthalmol Vis Sci* 47:3989-4000.
- Zhou C, Chen H, Lu F, Sellak H, Daigle JA, Alexeyev MF, Xi Y, Ju J, van Mourik JA, and Wu S (2007) Cav3.1 (x1G) controls von Willebrand factor secretion in rat pulmonary microvascular endothelial cells. Am J Physiol Lung Cell Mol Physiol 292:L833–L844.

Address correspondence to: Dr. Michael L. Paffett, Department of Cell Biology and Physiology, University of New Mexico, MSC08 4750, Albuquerque, NM 87131. E-mail: mpaffett@salud.unm.edu